IRIS
ELENA, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.930
AS - Asia 1.386
EU - Europa 1.211
SA - Sud America 194
AF - Africa 24
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.871
CN - Cina 743
IE - Irlanda 377
SG - Singapore 298
HK - Hong Kong 199
BR - Brasile 156
RU - Federazione Russa 156
FI - Finlandia 149
DE - Germania 136
IT - Italia 98
UA - Ucraina 91
GB - Regno Unito 53
VN - Vietnam 52
SE - Svezia 42
CA - Canada 34
FR - Francia 24
AR - Argentina 21
BE - Belgio 18
IN - India 18
MX - Messico 16
NL - Olanda 15
PL - Polonia 15
TR - Turchia 13
ES - Italia 10
JP - Giappone 10
AT - Austria 9
BD - Bangladesh 9
ZA - Sudafrica 9
AU - Australia 7
IQ - Iraq 6
AZ - Azerbaigian 5
LT - Lituania 5
CL - Cile 4
EC - Ecuador 4
EG - Egitto 4
ID - Indonesia 4
PY - Paraguay 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
EU - Europa 3
IL - Israele 3
JO - Giordania 3
KE - Kenya 3
KR - Corea 3
MA - Marocco 3
PK - Pakistan 3
AM - Armenia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
GR - Grecia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NZ - Nuova Zelanda 2
RO - Romania 2
SA - Arabia Saudita 2
TN - Tunisia 2
UZ - Uzbekistan 2
AL - Albania 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MQ - Martinica 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.758
Salva come PNG Salva come JPEG
Città #
Dublin 377
Chandler 232
Hong Kong 198
Dallas 197
Ashburn 175
Nanjing 163
Jacksonville 144
Singapore 135
Beijing 128
Boardman 110
Nanchang 67
Ann Arbor 63
Princeton 58
Lawrence 56
Medford 54
Los Angeles 53
Changsha 52
Wilmington 50
New York 48
Helsinki 47
Hebei 38
Jiaxing 37
Shenyang 36
Munich 34
Pavia 31
Redondo Beach 26
Shanghai 25
Moscow 24
Buffalo 22
Hangzhou 22
Ho Chi Minh City 21
Turku 21
Toronto 19
Brussels 18
Milan 16
São Paulo 15
Tianjin 15
Santa Clara 13
Belo Horizonte 12
Norwalk 12
Warsaw 12
Woodbridge 12
Atlanta 11
Hanoi 11
San Francisco 11
Seattle 11
Denver 10
Montreal 10
Chicago 9
Houston 9
London 9
Nuremberg 9
Tokyo 9
Brooklyn 8
Jinan 8
Orem 8
The Dalles 8
Ankara 7
Chennai 7
Guangzhou 7
Johannesburg 7
Frankfurt am Main 6
Mexico City 6
Vienna 6
Washington 6
Boston 5
Columbus 5
Fairfield 5
Falkenstein 5
Falls Church 5
Kunming 5
Manchester 5
Pune 5
Stockholm 5
Verona 5
Baku 4
Charlotte 4
Ningbo 4
Phoenix 4
Poplar 4
Taizhou 4
Amman 3
Amsterdam 3
Brasília 3
Campinas 3
Chongqing 3
Florence 3
Haiphong 3
Istanbul 3
Park Ridge 3
Porto Alegre 3
Redwood City 3
Reston 3
Seoul 3
Tappahannock 3
Vancouver 3
Zhengzhou 3
Asunción 2
Athens 2
Auckland 2
Totale 3.209
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 162
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 162
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 128
Blast phase of essential thrombocythemia: A single center study. 121
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 116
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 113
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 113
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 110
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 103
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 102
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 101
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 101
Clinical significance of somatic mutation in unexplained blood cytopenia 100
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 99
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms 98
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia 98
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications 91
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 90
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 90
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes 85
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 85
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 84
Relationship between clone metrics and clinical outcome in clonal cytopenia 83
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 81
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 80
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 79
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 79
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 78
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 77
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 76
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 76
Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis 74
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 74
Incidence and Prognosis of Clonal Hematopoiesis in patients with Chronic Idiopathic Neutropenia 74
‘Real-life’ study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis 73
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 73
Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications 72
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 72
Somatic mutations of calreticulin in myeloproliferative neoplasms 70
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 69
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia 69
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 69
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 69
Mutational status of myeloproliferative neoplasms. 66
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 66
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 65
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions 65
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 63
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis 63
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 60
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 57
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 57
A cross‐sectional study on quality of life in adult indolent systemic mastocytosis and its association with cutaneous involvement 52
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. 52
Validation of cytogenetic-based risk stratification in primary myelofibrosis. 48
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem? 46
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. 41
Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry 40
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. 38
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry 37
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series 31
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 27
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis 18
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry 14
Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia 12
Totale 4.937
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.381
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021151 0 0 0 0 0 18 12 40 17 32 21 11
2021/2022289 5 3 3 6 5 7 4 16 13 21 40 166
2022/2023836 77 60 5 43 80 61 0 38 423 6 30 13
2023/2024368 53 59 21 23 27 100 1 29 3 5 8 39
2024/2025947 22 71 26 21 28 63 62 67 211 34 126 216
2025/20261.262 152 204 283 284 252 87 0 0 0 0 0 0
Totale 4.937